CA3035147A1 - Depot systems comprising glatiramer acetate - Google Patents
Depot systems comprising glatiramer acetate Download PDFInfo
- Publication number
- CA3035147A1 CA3035147A1 CA3035147A CA3035147A CA3035147A1 CA 3035147 A1 CA3035147 A1 CA 3035147A1 CA 3035147 A CA3035147 A CA 3035147A CA 3035147 A CA3035147 A CA 3035147A CA 3035147 A1 CA3035147 A1 CA 3035147A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- depot formulation
- glatiramer
- depot
- symptom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Epoxy Resins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Chemical Vapour Deposition (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662381598P | 2016-08-31 | 2016-08-31 | |
| US62/381,598 | 2016-08-31 | ||
| PCT/IL2017/050882 WO2018042415A1 (en) | 2016-08-31 | 2017-08-09 | Depot systems comprising glatiramer acetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3035147A1 true CA3035147A1 (en) | 2018-03-08 |
Family
ID=61300274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3035147A Pending CA3035147A1 (en) | 2016-08-31 | 2017-08-09 | Depot systems comprising glatiramer acetate |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12370233B2 (enExample) |
| EP (2) | EP3506921B1 (enExample) |
| JP (1) | JP7193448B2 (enExample) |
| CN (1) | CN109982712A (enExample) |
| AU (1) | AU2017319728B2 (enExample) |
| BR (1) | BR112019003594A2 (enExample) |
| CA (1) | CA3035147A1 (enExample) |
| DK (1) | DK3506921T3 (enExample) |
| ES (2) | ES2952044T3 (enExample) |
| FI (1) | FI3506921T3 (enExample) |
| HR (2) | HRP20230738T1 (enExample) |
| HU (2) | HUE062393T2 (enExample) |
| IL (2) | IL301455B2 (enExample) |
| LT (1) | LT3506921T (enExample) |
| MX (1) | MX2019002284A (enExample) |
| PL (2) | PL3506921T3 (enExample) |
| PT (1) | PT3506921T (enExample) |
| RS (2) | RS66690B1 (enExample) |
| SI (1) | SI3506921T1 (enExample) |
| SM (2) | SMT202500136T1 (enExample) |
| WO (1) | WO2018042415A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| US11471421B2 (en) | 2016-08-28 | 2022-10-18 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| BR112019017724A2 (pt) | 2017-03-26 | 2020-03-31 | Mapi Pharma Ltd. | Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla |
| US11865213B2 (en) * | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| US12514908B2 (en) | 2021-07-05 | 2026-01-06 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| WO2023170493A1 (en) * | 2022-03-07 | 2023-09-14 | Hadidi Naghmeh | Drug delivery using a parenteral pharmaceutical composition |
| CA3244202A1 (en) | 2022-03-17 | 2023-09-21 | Mapi Pharma Ltd. | DEPOSIT SYSTEMS INCLUDING CARIPRAZINE OR SALTS THEREOF |
Family Cites Families (187)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| CN100391445C (zh) | 1996-01-24 | 2008-06-04 | 美国政府陆军部 | 新型的“非突发的”持续释放聚(丙交酯/乙交酯)的微球 |
| US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| DE3673317D1 (de) | 1985-10-11 | 1990-09-13 | Duphar Int Res | Automatische spritze. |
| GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| US5981485A (en) | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| HU221294B1 (en) | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5578442A (en) | 1992-03-23 | 1996-11-26 | Vivorx, Inc. | Graft copolymers of polycationic species and water-soluble polymers, and use therefor |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5643605A (en) | 1993-10-25 | 1997-07-01 | Genentech, Inc. | Methods and compositions for microencapsulation of adjuvants |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5858964A (en) | 1995-04-14 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD |
| IT1276690B1 (it) | 1995-06-09 | 1997-11-03 | Ira Srl | Sistema di inclusione a rilascio controllato di acido glicolico in beta-ciclodestrine e procedimento di preparazione di detto sistema |
| HU230048B1 (hu) | 1996-02-09 | 2015-06-29 | Abbvie Biotechnology Ltd | Humán TNFalfa-kötő antitestek alkalmazása |
| US5792477A (en) | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
| US20070185032A1 (en) | 1996-12-11 | 2007-08-09 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| US5945126A (en) | 1997-02-13 | 1999-08-31 | Oakwood Laboratories L.L.C. | Continuous microsphere process |
| AR012448A1 (es) | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
| US6454746B1 (en) | 1997-06-04 | 2002-09-24 | Eli Lilly And Company | Medication delivery apparatus |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| AU2868699A (en) | 1998-02-13 | 1999-08-30 | Autoimmune, Inc. | Treatment of multiple sclerosis using cop-1 and th2-enhancing cytokines |
| JP2003521448A (ja) | 1998-07-23 | 2003-07-15 | ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 合成ペプチドおよび自己免疫疾患治療のための使用方法 |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| WO2000005250A1 (en) | 1998-07-23 | 2000-02-03 | Yeda Research And Development Co., Ltd | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| EP2090583B1 (en) | 1998-09-25 | 2011-07-13 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| AU6281599A (en) | 1998-10-02 | 2000-04-26 | Yeda Research And Development Co. Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| AU775073C (en) | 1998-11-12 | 2007-05-03 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD |
| US6194006B1 (en) | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
| US20030104048A1 (en) | 1999-02-26 | 2003-06-05 | Lipocine, Inc. | Pharmaceutical dosage forms for highly hydrophilic materials |
| US6872739B1 (en) | 1999-06-04 | 2005-03-29 | Vereniging Voor Christelijk Wetenshappelikjk Onderwijs | Use of riluzole for the treatment of multiple sclerosis |
| US6531130B1 (en) | 1999-07-06 | 2003-03-11 | The Board Of Trustees Of The Leland Stanford University | Treatment of demyelinating autoimmune disease with ordered peptides |
| EP1248643B1 (en) | 2000-01-20 | 2005-08-17 | YEDA RESEARCH AND DEVELOPMENT Co. LTD. | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
| JP2003522799A (ja) | 2000-02-18 | 2003-07-29 | イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド・アット・ザ・ウェイズマン・インスティテュート・オブ・サイエンス | コポリマー１の経口、経鼻および経肺投与製剤 |
| ZA200206457B (en) | 2000-02-18 | 2003-08-13 | Yeda Res & Dev | Oral, nasal and pulmonary dosage formulations of copolymer 1. |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| PL363431A1 (en) | 2000-06-05 | 2004-11-15 | Teva Pharmaceuticals Industries, Ltd. | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| DE60116467T2 (de) | 2000-06-07 | 2006-11-02 | Yeda Research And Development Co., Ltd. | Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| KR100392501B1 (ko) | 2000-06-28 | 2003-07-22 | 동국제약 주식회사 | 다중 에멀젼법에 의한 서방출성 미립구의 제조방법 |
| WO2008150547A1 (en) | 2007-06-04 | 2008-12-11 | The Regents Of The University Of California | Pregnancy hormone combination for treatment of autoimmune diseases |
| US6835711B2 (en) | 2001-06-28 | 2004-12-28 | Yeda Research And Development Co. Ltd. | Use of poly-Glu,Tyr for neuroprotective therapy |
| AU2002320360B2 (en) | 2001-07-10 | 2005-05-26 | Teva Pharmaceutical Industries Ltd. | Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery |
| JP5010798B2 (ja) | 2001-10-03 | 2012-08-29 | プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 自己免疫疾患を抑制するためのコポリマー、及びその使用方法 |
| ES2367422T3 (es) | 2001-10-09 | 2011-11-03 | Amgen Inc. | Derivados de imidazol como agentes antiinflamatorios. |
| WO2003048207A2 (en) | 2001-11-28 | 2003-06-12 | Immunomedics, Inc. | Anti-dota antibody |
| CA2469393C (en) | 2001-12-04 | 2010-05-25 | Teva Pharmaceutical Industries, Ltd. | Processes for the measurement of the potency of glatiramer acetate |
| US7351686B2 (en) | 2001-12-06 | 2008-04-01 | Yeda Research And Development Co. Ltd. | Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides |
| US8871241B2 (en) | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
| CN1398584A (zh) | 2002-07-15 | 2003-02-26 | 裴福兴 | 一种bFGF－PLGA缓释微球及其制备方法和用途 |
| DE10237146A1 (de) | 2002-08-13 | 2004-03-04 | Medac Gesellschaft für klinische Spezialpräparate mbH | Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose |
| AU2003270701B2 (en) | 2002-10-31 | 2009-11-12 | Amgen Inc. | Antiinflammation agents |
| EP1565486A2 (en) | 2002-11-13 | 2005-08-24 | Apotex Pharmachem Inc. | Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine |
| CN100464796C (zh) | 2002-11-25 | 2009-03-04 | 特克法马许可公司 | 包括可复位安全释放设备的自动注射器 |
| WO2004060265A2 (en) | 2003-01-07 | 2004-07-22 | Yeda Research And Development Co. Ltd. | Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
| NZ569331A (en) | 2003-01-21 | 2010-08-27 | Yeda Res & Dev | COP 1 for treatment of inflammatory bowel diseases |
| EP1603530A1 (en) | 2003-03-04 | 2005-12-14 | Teva Pharmaceutical Industries Limited | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| HRP20140524T1 (hr) | 2003-05-14 | 2014-12-19 | Teva Pharmaceutical Industries Ltd. | Kombinacijska terapija glatiramer acetatom i mitoksantronom za lijeäśenje multiple skleroze |
| WO2005035088A2 (en) | 2003-07-18 | 2005-04-21 | Baxter International, Inc. | Method for preparing small spherical by controlled phase separation |
| US20050142205A1 (en) | 2003-07-18 | 2005-06-30 | Julia Rashba-Step | Methods for encapsulating small spherical particles prepared by controlled phase separation |
| US20060276390A1 (en) | 2003-07-31 | 2006-12-07 | Yeda Research And Development Co. Ltd. | Combined treatments comprising synthetic peptide copolymers for preventing graft rejection |
| US20050170004A1 (en) | 2003-10-31 | 2005-08-04 | Vered Rosenberger | Nanoparticles for drug delivery |
| EP1684797A1 (en) | 2003-11-12 | 2006-08-02 | Yeda Research and Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
| CA2553254C (en) | 2004-01-12 | 2013-12-17 | The Trustees Of The University Of Pennsylvania | Long-term delivery formulations and methods of use thereof |
| RU2006134701A (ru) | 2004-03-01 | 2008-04-10 | Пептиммьюн | Способы и композиции для лечения аутоиммунных заболеваний |
| CA2558380A1 (en) | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| US7576051B2 (en) | 2004-03-11 | 2009-08-18 | Sanyo Chemical Industries, Ltd. | Wound dressing for accelerating epidermal regeneration |
| MXPA06011021A (es) | 2004-03-25 | 2007-04-13 | Johnson & Johnson | Compuestos de imidazol. |
| US20060194725A1 (en) | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| RU2410115C2 (ru) | 2004-05-07 | 2011-01-27 | Пептиммьюн, Инк. | Способы лечения заболеваний с помощью статистических сополимеров |
| EP1753455A2 (en) | 2004-06-04 | 2007-02-21 | Genentech, Inc. | Method for treating multiple sclerosis |
| US8053197B2 (en) | 2004-07-30 | 2011-11-08 | Oregon Health & Science University | Methods for detecting and treating autoimmune disorders |
| CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| CA2579038A1 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| DK1797109T3 (en) | 2004-09-09 | 2016-04-11 | Yeda Res & Dev | MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof |
| NZ554018A (en) | 2004-09-09 | 2009-06-26 | Teva Pharma | Process for preparation of trifluoroacetyl glatiramer acetate using purified hydrobromic acid |
| WO2006050122A1 (en) | 2004-10-29 | 2006-05-11 | Sandoz Ag | Processes for preparing glatiramer |
| JP2008520717A (ja) | 2004-11-19 | 2008-06-19 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 多発性硬化症についての処置 |
| EP1827108B1 (en) | 2004-11-29 | 2015-04-08 | Yeda Research And Development Co., Ltd. | Induction of neurogenesis and stem cell therapy in combination with copolymer 1 |
| AU2006211101A1 (en) | 2005-02-02 | 2006-08-10 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Synthetic peptide copolymers for treatment and prevention of cardiovascular disorders |
| US20060172942A1 (en) | 2005-02-02 | 2006-08-03 | Teva Pharmaceutical Industries, Ltd. | Process for producing polypeptide mixtures using hydrogenolysis |
| WO2006089066A1 (en) | 2005-02-15 | 2006-08-24 | Neuromolecular Pharmaceuticals, Inc. | Combinations therapy for treatment of demyelinating conditions |
| HRP20130622T1 (en) | 2005-02-17 | 2013-08-31 | Teva Pharmaceutical Industries Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| EP1891233A4 (en) | 2005-04-25 | 2010-03-24 | Yeda Res & Dev | MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE |
| KR20080016659A (ko) | 2005-05-20 | 2008-02-21 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제의 억제제로서 유용한 피롤로피리딘 |
| WO2007021970A2 (en) | 2005-08-15 | 2007-02-22 | Praecis Pharmaceuticals, Inc. | Stable pharmaceutical formulations and methods of use thereof |
| WO2007030573A2 (en) | 2005-09-09 | 2007-03-15 | Yeda Research And Development Co. Ltd. | Polypeptides useful for molecular weight determinations |
| US7517856B2 (en) | 2005-10-11 | 2009-04-14 | Ben-Gurion University Of The Negev Research And Development Authority | Bioconjugates comprising sulfated polysaccharides and their uses |
| US20070161566A1 (en) | 2006-01-11 | 2007-07-12 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| HUE047230T2 (hu) | 2006-02-28 | 2020-04-28 | Biogen Ma Inc | Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei |
| CA2641160A1 (en) | 2006-02-28 | 2007-09-07 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds |
| CA2680333C (en) | 2006-03-15 | 2016-10-25 | The Brigham And Women's Hospital, Inc. | Use of gelsolin to treat multiple sclerosis and to diagnose neurologic diseases |
| ES2565035T3 (es) | 2006-04-28 | 2016-03-30 | Momenta Pharmaceuticals, Inc. | Métodos para evaluar mezclas de péptidos |
| WO2007146331A1 (en) | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Tannate salt form of polypeptide mixtures, their preparation and use |
| ES2605154T3 (es) | 2006-06-28 | 2017-03-13 | Yeda Research And Development Company Limited | Copolímero 1 para el tratamiento de la degeneración macular relacionada con la edad |
| TWI498137B (zh) | 2006-06-30 | 2015-09-01 | Abbvie Biotechnology Ltd | 自動注射裝置 |
| ES2338488T3 (es) | 2006-07-05 | 2010-05-07 | Momenta Pharmaceuticals, Inc. | Proceso mejorado para la preparacion de copolimero-1. |
| WO2008060786A2 (en) | 2006-10-06 | 2008-05-22 | Baxter International Inc. | Microencapsules containing surface-modified microparticles and methods of forming and using the same |
| CN101562977A (zh) | 2006-12-15 | 2009-10-21 | 艾博特公司 | 新的二唑化合物 |
| WO2008075365A1 (en) | 2006-12-20 | 2008-06-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods for treatment of age related degeneration of the retina |
| PT2139467T (pt) | 2007-02-08 | 2016-12-16 | Biogen Ma Inc | Neuroproteção em doenças desmielinizantes |
| WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
| PT2187882E (pt) | 2007-07-11 | 2013-04-17 | Medicinova Inc | Tratamento de uma doença neurodegenerativa progressiva com ibudilast |
| US8193147B2 (en) | 2007-09-24 | 2012-06-05 | Hadasit Medical Research Services & Development Ltd. | Use of copolymer 1 for treatment of muscular dystrophy |
| MX2010003113A (es) | 2007-09-25 | 2010-04-01 | Abbott Lab | Compuestos de octahidropentaleno como antagonistas del receptor de quimiocina. |
| WO2009042892A1 (en) | 2007-09-26 | 2009-04-02 | Oregon Health & Science University | Cyclic undecapeptides and derivatives as multiple sclerosis therapies |
| WO2009063459A2 (en) | 2007-11-13 | 2009-05-22 | Yeda Research And Development Co. Ltd | Synthetic peptide copolymers for treatment of neurodevelopmental disorders |
| CN101877963A (zh) | 2007-11-28 | 2010-11-03 | 泰华制药工业有限公司 | 延缓临床确诊的多发性硬化症发作的方法 |
| ES2329327B1 (es) | 2008-03-19 | 2010-09-17 | Proyecto De Biomedicina Cima, S.L. | Combinaciones sinergicas de 5'-metiltioadenosina. |
| EP2318012A4 (en) | 2008-07-25 | 2011-08-24 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING AUTOMINATION DISEASES |
| EP2341904A1 (en) | 2008-08-26 | 2011-07-13 | Fibrogen, Inc. | Methods for treatment of multiple sclerosis |
| CL2009001841A1 (es) | 2008-09-10 | 2011-02-18 | Acorda Therapeutics Inc | Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto. |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | 建南德克公司 | 治療進展型多發性硬化症之方法 |
| JP2012505257A (ja) | 2008-10-13 | 2012-03-01 | バイオヴィスタ，インコーポレイテッド | 多発性硬化症治療のための組成物および方法 |
| AU2009324495B2 (en) | 2008-12-11 | 2015-12-24 | Biovista, Inc. | Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles |
| BRPI1008602A8 (pt) | 2009-02-18 | 2018-01-02 | Eyeon Particle Sciences Llc | uso de co-polímero bi-funcional para as aplicações oftálmicas e outras aplicações tópicas e locais |
| EP2246048A1 (en) | 2009-04-30 | 2010-11-03 | Santhera Pharmaceuticals (Schweiz) AG | Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis |
| NZ577731A (en) | 2009-06-16 | 2010-08-27 | Innate Therapeutics Ltd | Compositions and methods for treatment of multiple sclerosis |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| PL2275086T3 (pl) | 2009-07-15 | 2012-09-28 | Teva Pharma | Formulacja octanu glatirameru o zredukowanej objętości oraz sposoby podawania |
| AU2013203367C1 (en) | 2009-08-20 | 2018-01-18 | Yeda Research & Development Co., Ltd | Low frequency glatiramer acetate therapy |
| SG10201405806SA (en) | 2009-08-20 | 2014-11-27 | Yeda Res & Dev | Low Frequency Glatiramer Acetate Therapy |
| ES2664727T3 (es) | 2009-10-22 | 2018-04-23 | University College Dublin National University Of Ireland, Dublin | Terapia causal de enfermedades o estados asociados con desmielinización del SNC o del SNP |
| ES2699692T3 (es) * | 2010-01-04 | 2019-02-12 | Mapi Pharma Ltd | Sistema de depósito que comprende acetato de glatiramer |
| US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US20130046015A1 (en) | 2010-02-11 | 2013-02-21 | Robert C. Axtell | Therapeutic Inhibition of Granulocyte Function in Demyelinating Disease |
| PT2533634E (pt) | 2010-02-12 | 2015-12-28 | Biogen Ma Inc | Neuroproteção em doenças desmielinizantes |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| EP2529757B1 (en) * | 2011-05-31 | 2014-01-08 | Laboratorios Farmaceuticos Rovi, S.A. | Paliperidone implant formulation |
| AU2011282635B2 (en) | 2010-07-29 | 2015-05-28 | Dr. Reddy's Laboratories Ltd. | Glatiramer acetate molecular weight markers |
| EP2605797A2 (en) * | 2010-08-20 | 2013-06-26 | Cerulean Pharma Inc. | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods |
| ES2602977T3 (es) | 2010-10-11 | 2017-02-23 | Teva Pharmaceutical Industries Ltd. | Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero |
| GB2485169A (en) | 2010-11-03 | 2012-05-09 | Univ Jw Goethe Frankfurt Main | (R)-flurbiprofen for use in the treatment of multiple sclerosis |
| EP2500072A1 (en) | 2011-03-15 | 2012-09-19 | LEK Pharmaceuticals d.d. | A novel process of residual solvent removal |
| US20120328567A1 (en) | 2011-04-08 | 2012-12-27 | Steven Bushnell | Biomarkers predictive of therapeutic responsiveness to ifnb and uses thereof |
| US9409987B2 (en) | 2011-04-15 | 2016-08-09 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
| WO2012143924A1 (en) | 2011-04-21 | 2012-10-26 | Mapi Pharma Ltd. | Random pentapolymer for treatment of autoimmune diseases |
| FI3467509T3 (fi) | 2011-05-04 | 2026-02-11 | Cellular Tech Ltd | Cns-antigeenispesifisiä b-solu-, t-solu- ja vasta-ainemäärityksiä ja niiden käyttötapoja multippeliskleroosin diagnosoinnissa ja hoidossa |
| WO2012150495A1 (en) | 2011-05-05 | 2012-11-08 | National Institute Of Immunology | Synthetic peptides and random copolymers for the treatment of autoimmune disorders |
| AU2012323345A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| WO2013138244A2 (en) | 2012-03-12 | 2013-09-19 | Medimmune, Llc | Treatment of multiple sclerosis with anti-cd19 antibody |
| GB201208850D0 (en) | 2012-05-18 | 2012-07-04 | Alphaptose Gmbh | Tri-subsituted glycerol compounds for use in the treatment of clinically isolated syndrome and/or multiple sclerosis |
| US9132138B2 (en) | 2012-08-27 | 2015-09-15 | Casi Pharmaceuticals, Inc. | Method for the treatment of multiple sclerosis |
| CN104870014A (zh) | 2012-10-09 | 2015-08-26 | 比奥根Ma公司 | 联合治疗及用于治疗脱髓鞘病症的用途 |
| MX2015004563A (es) | 2012-10-10 | 2015-07-14 | Teva Pharma | Biomarcadores predictivos para respuesta clinica para acetato de glatiramero. |
| EP2941274A4 (en) | 2013-01-04 | 2016-11-16 | Teva Pharma | CHARACTERIZATION OF A MEDICINAL PRODUCT ASSOCIATED WITH GLATIRAMÈRE ACETATE |
| ES2859553T3 (es) | 2013-01-08 | 2021-10-04 | Pathologica Llc | Mitoguazona para el tratamiento de esclerosis múltiple progresiva |
| WO2014127139A1 (en) | 2013-02-15 | 2014-08-21 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| TW201521757A (zh) | 2013-03-12 | 2015-06-16 | Teva Pharma | 先後通過利妥昔單抗（ｒｉｔｕｘｉｍａｂ）誘導治療及格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）治療 |
| WO2014145203A2 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Systems and methods for characterization of multiple sclerosis |
| CN103169670B (zh) * | 2013-03-22 | 2016-07-06 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷微球及其制备方法 |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| AU2014319921A1 (en) | 2013-09-11 | 2016-03-17 | Compugen Ltd. | Anti-VSTM5 antibodies and the use thereof in therapy and diagnosis |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US10493122B2 (en) | 2014-03-17 | 2019-12-03 | Mapi Pharma Ltd. | Sublingual delivery of glatiramer acetate |
| EP3137087B1 (en) | 2014-04-28 | 2023-09-06 | The Regents of the University of California | Estrogen combination for treatment of multiple sclerosis |
| WO2016036721A1 (en) | 2014-09-02 | 2016-03-10 | The Regents Of The University Of California | Estrogen receptor ligand treatment for neurodegenerative diseases |
| WO2016036719A1 (en) | 2014-09-02 | 2016-03-10 | The Regents Of The University Of California | Estrogen therapy for brain gray matter atrophy and associated disability |
| WO2016040861A1 (en) | 2014-09-12 | 2016-03-17 | Biogen Ma Inc. | Systems and methods for characterization of multiple sclerosis |
| WO2016064997A1 (en) | 2014-10-22 | 2016-04-28 | The Regents Of The University Of California | Compositions and methods for treating fatigue and depression |
| JP2018504400A (ja) | 2015-01-08 | 2018-02-15 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用 |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| US20160213633A1 (en) | 2015-01-28 | 2016-07-28 | Teva Pharmaceutical Industries, Ltd. | Method of inducing anti-glatiramer acetate antibody response |
| WO2016160830A1 (en) | 2015-03-30 | 2016-10-06 | The Regents Of The University Of California | Methods of providing neuroprotective therapy |
| EP3277285B1 (en) | 2015-03-30 | 2024-07-17 | The Regents of the University of California | Estriol for reducing cortical gray matter atrophy |
| WO2018002930A1 (en) * | 2016-06-30 | 2018-01-04 | Stem Cell Medicine Ltd. | Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells |
| US11471421B2 (en) * | 2016-08-28 | 2022-10-18 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| BR112019017724A2 (pt) | 2017-03-26 | 2020-03-31 | Mapi Pharma Ltd. | Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla |
| WO2018211486A1 (en) | 2017-05-15 | 2018-11-22 | Stem Cell Medicine Ltd. | Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells |
-
2017
- 2017-08-09 CN CN201780068092.9A patent/CN109982712A/zh active Pending
- 2017-08-09 PL PL17845658.8T patent/PL3506921T3/pl unknown
- 2017-08-09 US US16/328,582 patent/US12370233B2/en active Active
- 2017-08-09 RS RS20250341A patent/RS66690B1/sr unknown
- 2017-08-09 ES ES17845658T patent/ES2952044T3/es active Active
- 2017-08-09 ES ES23173177T patent/ES3023741T3/es active Active
- 2017-08-09 JP JP2019508893A patent/JP7193448B2/ja active Active
- 2017-08-09 BR BR112019003594-0A patent/BR112019003594A2/pt not_active Application Discontinuation
- 2017-08-09 WO PCT/IL2017/050882 patent/WO2018042415A1/en not_active Ceased
- 2017-08-09 AU AU2017319728A patent/AU2017319728B2/en active Active
- 2017-08-09 SM SM20250136T patent/SMT202500136T1/it unknown
- 2017-08-09 IL IL301455A patent/IL301455B2/en unknown
- 2017-08-09 PL PL23173177.9T patent/PL4252849T3/pl unknown
- 2017-08-09 SM SM20230251T patent/SMT202300251T1/it unknown
- 2017-08-09 HR HRP20230738TT patent/HRP20230738T1/hr unknown
- 2017-08-09 HR HRP20250396TT patent/HRP20250396T1/hr unknown
- 2017-08-09 CA CA3035147A patent/CA3035147A1/en active Pending
- 2017-08-09 EP EP17845658.8A patent/EP3506921B1/en active Active
- 2017-08-09 MX MX2019002284A patent/MX2019002284A/es unknown
- 2017-08-09 RS RS20230617A patent/RS64445B1/sr unknown
- 2017-08-09 PT PT178456588T patent/PT3506921T/pt unknown
- 2017-08-09 FI FIEP17845658.8T patent/FI3506921T3/fi active
- 2017-08-09 SI SI201731391T patent/SI3506921T1/sl unknown
- 2017-08-09 HU HUE17845658A patent/HUE062393T2/hu unknown
- 2017-08-09 EP EP23173177.9A patent/EP4252849B1/en active Active
- 2017-08-09 DK DK17845658.8T patent/DK3506921T3/da active
- 2017-08-09 LT LTEPPCT/IL2017/050882T patent/LT3506921T/lt unknown
- 2017-08-09 HU HUE23173177A patent/HUE071047T2/hu unknown
-
2019
- 2019-02-19 IL IL264914A patent/IL264914B2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017319728B2 (en) | Depot systems comprising glatiramer acetate | |
| US12343371B2 (en) | Method for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using a sustained release depot formulation comprising glatiramer acetate | |
| US8377885B2 (en) | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof | |
| AU2010337822A1 (en) | Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof | |
| TW201138805A (en) | Composition of organic compounds | |
| USRE50301E1 (en) | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof | |
| HK40005874A (en) | Depot systems comprising glatiramer acetate | |
| HK40010052A (en) | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220516 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240729 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240729 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250415 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250806 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250806 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250807 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250813 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250916 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250916 |